vTv Therapeutics Inc. — Q1 2021 Form 10-Q
Business context and period: Clinical-stage pharmaceutical company focused on metabolic and inflammatory diseases. This unaudited report covers the three months ended March 31, 2021, with comparisons to Q1 2020. vTv has no product-sales revenue; reported revenue is primarily from licensing and collaboration arrangements.
Financial results and liquidity
| Metric | Q1 2021 | Q1 2020 / prior-period reference |
|---|---|---|
| Revenue | $987,000 | $8,000 |
| Research and development expense | $3.1 million | $4.2 million |
| General and administrative expense | $2.2 million | $2.5 million |
| Operating loss | $4.3 million | $6.6 million |
| Net loss attributable to vTv | $4.2 million | $4.7 million |
| Basic and diluted loss per Class A share | $0.08 | $0.11 |
| Cash used in operating activities | $5.3 million | $5.6 million |
| Cash and cash equivalents, March 31 | $8.4 million | $5.7 million at December 31, 2020 |
Q1 revenue reflects approximately $1.0 million recognized after a January amendment to the Huadong license agreement, which removed vTv’s obligation to sponsor and contribute up to $3.0 million to a Phase 2 trial. The filing does not report a meaningful gross margin; the company remains loss-making. Financing activities provided $8.0 million, principally from issuing 3.5 million Class A shares under the Lincoln Park agreement. Cash increased $2.7 million during the quarter.
At March 31, current assets were $9.2 million and current liabilities were $5.2 million. The company had no notes payable outstanding: its prior loan was fully repaid in December 2020. Operating lease liabilities totaled $795,000. The balance sheet also included a $4.5 million related-party warrant liability, remeasured through earnings.
Changes versus Q1 2020
- Revenue rose from $8,000 to $987,000, primarily due to the Huadong contract modification and cumulative revenue recognition.
- Operating expenses declined $1.4 million. R&D expense fell $1.1 million, mainly because azeliragon development costs decreased after that program’s discontinuation for Alzheimer’s disease in patients with type 2 diabetes, partly offset by $1.0 million of higher HPP737 study spending.
- Net loss attributable to vTv narrowed by $483,000, despite a $1.3 million increase in other expense, principally the fair-value loss on related-party warrants. No interest expense was incurred in Q1 2021 after repayment of the loan; Q1 2020 included $168,000.
- Financing cash flow increased to $8.0 million from $4.2 million, reflecting Q1 2021 equity sales and lower loan repayments.
Outlook, management commentary and risks
- Going concern: Management said available cash, remaining ATM capacity and Lincoln Park proceeds through May 5, 2021 were expected to fund operations only through the end of Q3 2021. The company stated that these conditions raise substantial doubt about its ability to continue as a going concern. Additional financing is not assured and could dilute shareholders or impose restrictions.
- Pipeline: vTv is developing TTP399 for type 1 diabetes and HPP737 for psoriasis. It expected top-line results from the HPP737 Phase 1 multiple-ascending-dose study in Q3 2021 and planned to consider a Phase 2 psoriasis study based on results. TTP399’s Phase 1 mechanistic study was expected to report top-line results in Q3 2021; pivotal-study design remained under discussion with the FDA.
- Subsequent development: In April 2021, after quarter-end, the FDA granted TTP399 Breakthrough Therapy designation. This is not approval; the filing says the company was seeking FDA input on pivotal and registrational study design.
- Other funding and commercial arrangements: The company is evaluating equity financing and seeking additional partnerships. License milestone and royalty receipts are uncertain; the filing reports no revenue from drug sales and no committed external funding beyond its ATM and Lincoln Park arrangements.
- Key risks: Clinical and regulatory outcomes, trial enrollment and costs, access to financing, dilution, intellectual-property protection, commercialization prospects and the effect of COVID-19. The company reported no material legal proceedings, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Whether new funding or partnerships were secured and whether the stated runway beyond Q3 2021 was extended.
- Subsequent cash burn, ATM and Lincoln Park share sales, and resulting dilution; 441,726 additional shares were sold to Lincoln Park after quarter-end for approximately $1.0 million gross proceeds.
- FDA feedback and the timing, design, funding and results of TTP399 pivotal studies and the mechanistic study.
- HPP737 Phase 1 results and whether a Phase 2 psoriasis trial proceeded as planned.
- Future milestone, royalty and collaboration revenue, which is uncertain and distinct from product-sales revenue.